Chondrosarcoma of the Mandible: A Clinicopathological Case Report based Insight

SNEHANJAN SARANGI; Debarati Ray; Abhishek Ghosh; Tathagata Bhattacharjee

doi:10.21276/ujds.2026.12.2.17

SNEHANJAN SARANGI Assistant Professor, Department of Oral Pathology, Dr. R Ahmed Dental College, Kolkata
Debarati Ray Associate Professor, Department of Oral Pathology
Abhishek Ghosh Consultant Oral Pathologist, Department of Oral Pathology
Tathagata Bhattacharjee Associate Professor, Department of Oral Pathology

DOI: https://doi.org/10.21276/ujds.2026.12.2.17

Keywords: Atypical chondrocytes, Chondrosarcoma, Mandible, Oral malignancy, Sunburst appearance

Abstract

Chondrosarcoma is a malignant mesenchymal tumour characterized by the production of cartilaginous matrix. Its occurrence within the maxillofacial region is uncommon and frequently presents a diagnostic dilemma because its clinical and radiographic features can resemble other primary bone malignancies. A 70-year-old male presented with a gradually enlarging and painful swelling involving the left side of the mandible over a period of approximately six months. Clinical examination revealed a diffuse extraoral swelling along with an intraoral exophytic and ulcerated lesion in the posterior alveolar region. Imaging studies demonstrated irregular radiopaque areas associated with cortical destruction and a characteristic sunburst-type periosteal reaction. Histopathological examination showed atypical chondrocytes embedded within a chondroid matrix, along with areas of calcification and cellular pleomorphism, confirming the diagnosis of chondrosarcoma. This case highlights the aggressive nature of mandibular chondrosarcoma and emphasizes the importance of correlating clinical, radiographic, and histopathological findings to arrive at a definitive diagnosis and guide appropriate treatment.

References

[1] Gelderblom H, Hogendoorn PC, Dijkstra SD, Van Rijswijk CS, Krol AD, Taminiau AH, et al. The clinical approach towards chondrosarcoma. The oncologist. 2008;13:320-9. https://doi.org/10.1634/theoncologist.2007-0237

[2] Chekaraou SM, Abdoul HRA, Dandi AM, Habibou AM, Waly M, Kadre OKA. Mandibular chondrosarcoma grade 2: a case report highlighting disease aggressiveness. Int J Surg Case Rep. 2026;138:250-53. doi: 10.1097/RC9.0000000000000071

[3] Karimi A, Derakhshan S, Mosavat F, Gholamhoseini Z, Khiavi MM. Mesenchymal chondrosarcoma of the mandible, a big dilemma: report of a rare case in mesenchymal chondrosarcoma of the mandible—report of a case with discussion of diagnostic and therapeutic dilemmas. Case Reports in Dentistry. 2024;2024:8884697. https://doi.org/10.1155/2024/8884697

[4] Mordovskiy AV, Epifanov SA, Polyakov AP, Novikova IV. Chondrosarcoma of temporomandibular joint: report of two Cases. Indian J Otolaryngol Head Neck Surg. 2024;76:4828–33.https://doi.org/10.1007/s12070-024-04883-6

[5] AlSanawi H, Albishi W, AlDhaheri M, AlMugren T, AlAmer N. Chondrosarcoma of the proximal radius treated by wide resection and reconstructed by 3D printed implant: a case report and description of surgical technique. International Journal of Surgery Case Reports. 2022;91:106770. https://doi.org/10.1016/j.ijscr.2022.106770

[6] Oh HJ, Yoon HJ, Huh KH, Kim B, Kwon IJ, Kim SM, et al. Surgical management and final outcomes of chondrosarcoma of the temporomandibular joint: case series and comprehensive literature review. World Journal of Surgical Oncology. 2023;21:253.https://doi.org/10.1186/s12957-023-03143-1

[7] Patrichi AI, Gurzu S. Pathogenetic and molecular classifications of soft tissue and bone tumors: A 2024 update. Pathology-Research and Practice. 2024;260:155406. https://doi.org/10.1016/j.prp.2024.155406

[8] van Praag VM, Rueten-Budde AJ, Ho V, Dijkstra PD, van der Geest IC, Bramer JA, et al. Incidence, outcomes and prognostic factors during 25 years of treatment of chondrosarcomas. Surgical oncology. 2018;27:402-8. https://doi.org/10.1016/j.suronc.2018.05.009

[9] Ollivier L, Vanel D, Leclère J. Imaging of chondrosarcomas. Cancer Imaging. 2003;4:36. https://doi.org/10.1102/1470-7330.2003.0022

[10] Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone. A clinicopathologic analysis with emphasis on histologic grading. Cancer. 1977;40:818-31. https://doi.org/10.1002/1097-0142(197708)40:2%3C818::AID-CNCR2820400234%3E3.0.CO;2-B

[11] Li L, Tao W, Eid JE, Gupta S, Zheng S, Taswell CS, et al. Advances in Radiation Therapy for Primary Bone Malignancies. Technology in Cancer Research & Treatment. 2026;25:15330338261425345. https://doi.org/10.1177/15330338261425345

[12] Italiano A, Mir O, Cioffi A, Palmerini E, Piperno-Neumann S, Perrin C, et al. Advanced chondrosarcomas: role of chemotherapy and survival. Annals of oncology. 2013;24:2916-22. https://doi.org/10.1093/annonc/mdt374

[13] Jang BG, Huh KH, Kang JH, Kim JE, Yi WJ, Heo MS, et al. Imaging features of chondrosarcoma of the temporomandibular joint: report of nine cases and literature review. Clinical Radiology. 2020;75:878-e1. https://doi.org/10.1016/j.crad.2020.07.016

[14] Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. The Journal of pathology. 2011;224:334-43. https://doi.org/10.1002/path.2913

[15] Agulnik M, Wilky BA, Thorpe SW, Zuckerman LM. Chondrosarcoma: Clinical behavior, molecular mechanisms, and emerging therapeutic strategies. Critical Reviews in Oncology/Hematology. 2026;218:105075. https://doi.org/10.1016/j.critrevonc.2025.105075